Accolade Results Presentation Deck
10
Fiscal Fourth Quarter and FY22 Guidance
YOY Change
(midpoint)
Revenue
■
Revenue (pro forma*)
Adjusted EBITDA (Loss)**
Notes
Q4 FY 22
$90mm $93mm
-
$90mm $93mm
$(4)mm - $(8)mm
54%
13%
(319)%
FY 22
$306mm - $309mm
$(48)mm - $(52)mm
(16% -17%)
YOY Change
(midpoint)
81%
30%
(86)%
Approximately $8mm of performance-based revenue has been recognized sooner than expected FYTD (previously
expected in FQ4). YoY FQ4 growth including impact of revenue timing is 24% on pro forma basis at mid-point of
guidance
FQ4 Adjusted EBITDA Loss impacted by timing of PG revenue recognition
*. Pro forma operating results give effect to the acquisitions of 2nd.MD and PlushCare as if they had occurred on March 1, 2020.
**Adjusted EBITDA (Loss) excludes depreciation and amortization, acquisition and integration-related costs, stock-based compensation, and change in fair value of contingent consideration.
See Appendix for disclosures and reconciliations related to preliminary guidance for fiscal years ending February 28, 2022 and 2023View entire presentation